Serum Alpha-Fetoprotein Predicts Treatment Outcome in Chronic Hepatitis C Patients Regardless of HCV Genotype 英文参考文献.docVIP

下载本文档

6
0
约1.58万字
约 4页
2017-05-13 发布于上海
举报
版权申诉

Serum Alpha-Fetoprotein Predicts Treatment Outcome in Chronic Hepatitis C Patients Regardless of HCV Genotype 英文参考文献.doc

1、本文档共4页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Serum Alpha-Fetoprotein Predicts Treatment Outcome in Chronic Hepatitis C Patients Regardless of HCV Genotype 英文参考文献

SerumAlpha-FetoproteinPredictsTreatmentOutcome inChronicHepatitisCPatientsRegardlessofHCV Genotype HendyAbdoul1,VincentMallet2,StanislasPol2,ArnaudFontanet1* 1Unite′ d’E′pide′miologiedesMaladiesE′mergentes,InstitutPasteur,Paris,France,2Universite′ ParisDescartes,APHP,Ho?pitalCochin,Unite′ d’he′patologie,INSERMU.567, Paris,France Abstract Weexaminedtheassociationbetweenserumalpha-fetoprotein(AFP)levelandsustainedvirologicalresponse(SVR)in93 chronichepatitisCpatients.TheSVRratewasmuchhigheramongpatientswithserumAFPlevelsbelowratherthanabove themedianvalue(5.7ng/ml)(58.7%and19.2%,respectively;P,0.0001).SerumAFPshouldbeaddedtothelistoffactors predictiveoftreatmentresponseinchronichepatitisC. Citation:AbdoulH,MalletV,PolS,FontanetA(2008)SerumAlpha-FetoproteinPredictsTreatmentOutcomeinChronicHepatitisCPatientsRegardlessofHCV Genotype.PLoSONE3(6):e2391.doi:10.1371/journal.pone.0002391 Editor:DouglasF.Nixon,UniversityofCaliforniaSanFrancisco,UnitedStatesofAmerica ReceivedFebruary6,2008;AcceptedMay3,2008;PublishedJune11,2008 Copyright: ? 2008 Abdoul et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricteduse,distribution,andreproductioninanymedium,providedtheoriginalauthorandsourcearecredited. Funding:Theauthorshavenosupportorfundingtoreport. CompetingInterests:Theauthorshavedeclaredthatnocompetinginterestsexist. *E-mail:fontanet@pasteur.fr Introduction A1F1. Exclusion criteria were classic contraindications to interferon or ribavirin therapy, including autoimmune disorders, pregnancy,limitingpsychiatric,ophthalmologicalorcardiological disorders,plateletcountlessthan75,000/mm3,neutrophilcounts lessthan1500cells/mm3,andhaemoglobinlevelslessthan10g/ dl. Child-Pugh Ccirrhosis, andpositive hepatitis Bantigen were also excluded. Antiviral therapy included pegylated interferon alpha-2b (PEG intron, Schering Plough) and ribavirin (Rebetol, Schering Plough), initially given as a function of t